Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Corrigendum to "Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and In Vitro Efficacy Analysis" [Neoplasia 19.9 (2017) 716-733].

Tati S, Fisk JC, Abdullah J, Karacosta L, Chrisikos T, Philbin P, Morey S, Ghazal D, Zalzala F, Jessee J, Quataert S, Koury S, Moreno D, Eng JY, Glinsky VV, Glinskii OV, Sesay M, Gebhard AW, Birthare K, Olson JR, Rittenhouse-Olson K.

Neoplasia. 2018 Jan;20(1):118. doi: 10.1016/j.neo.2017.10.001. No abstract available.

2.

Quality Tuberculosis Care in Indonesia: Using Patient Pathway Analysis to Optimize Public-Private Collaboration.

Surya A, Setyaningsih B, Suryani Nasution H, Gita Parwati C, Yuzwar YE, Osberg M, Hanson CL, Hymoff A, Mingkwan P, Makayova J, Gebhard A, Waworuntu W.

J Infect Dis. 2017 Nov 6;216(suppl_7):S724-S732. doi: 10.1093/infdis/jix379.

3.

Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and InVitro Efficacy Analysis.

Tati S, Fisk JC, Abdullah J, Karacosta L, Chrisikos T, Philbin P, Morey S, Ghazal D, Zazala F, Jessee J, Quataert S, Koury S, Moreno D, Eng JY, Glinsky VV, Glinskii OV, Sesay M, Gebhard AW, Birthare K, Olson JR, Rittenhouse-Olson K.

Neoplasia. 2017 Sep;19(9):716-733. doi: 10.1016/j.neo.2017.07.001. Epub 2017 Aug 19. Erratum in: Neoplasia. 2018 Jan;20(1):118.

4.

Health system factors influencing management of multidrug-resistant tuberculosis in four European Union countries - learning from country experiences.

de Vries G, Tsolova S, Anderson LF, Gebhard AC, Heldal E, Hollo V, Cejudo LS, Schmid D, Schreuder B, Varleva T, van der Werf MJ.

BMC Public Health. 2017 Apr 19;17(1):334. doi: 10.1186/s12889-017-4216-9.

5.

Infection control and tuberculosis among health care workers in Viet Nam, 2009-2013: a cross-sectional survey.

Tiemersma EW, Huong NT, Yen PH, Tinh BT, Thuy TT, Van Hung N, Mai NT, Verver S, Gebhard A, Nhung NV.

BMC Infect Dis. 2016 Nov 10;16(1):664.

6.

Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda.

Mitnick CD, Rodriguez CA, Hatton ML, Brigden G, Cobelens F, Grobusch MP, Horsburgh R, Lange C, Lienhardt C, Oren E, Podewils LJ, Seaworth B, van den Hof S, Daley CL, Gebhard AC, Wares F; RESIST-TB (Research Excellence to Stop TB Resistance) and GDI (Global Drug Resistant TB Initiative).

PLoS One. 2016 May 25;11(5):e0155968. doi: 10.1371/journal.pone.0155968. eCollection 2016. Review.

7.

The Effects of Psycho-Emotional and Socio-Economic Support for Tuberculosis Patients on Treatment Adherence and Treatment Outcomes - A Systematic Review and Meta-Analysis.

van Hoorn R, Jaramillo E, Collins D, Gebhard A, van den Hof S.

PLoS One. 2016 Apr 28;11(4):e0154095. doi: 10.1371/journal.pone.0154095. eCollection 2016. Review.

8.

No evidence that pyrazinamide resistance is acquired after fluoroquinolone resistance.

Cobelens F, Gebhard A, van den Hof S.

Int J Tuberc Lung Dis. 2016 Feb;20(2):282. doi: 10.5588/ijtld.15.0628. No abstract available.

PMID:
26792486
9.

How Do the New Definitions for Multidrug-Resistant Tuberculosis Treatment Outcomes Really Perform?

Gebhard A, van den Hof S, Cobelens F.

Am J Respir Crit Care Med. 2015 Jul 1;192(1):117. doi: 10.1164/rccm.201503-0517LE. No abstract available.

PMID:
26131997
10.

First joint meeting of three European tuberculosis networks.

van der Werf MJ, Erkens C, Gebhard A, Voitzwinkler F, Dara M.

Euro Surveill. 2013 Sep 12;18(37). pii: 20583. No abstract available.

11.

MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma.

Gebhard AW, Jain P, Nair RR, Emmons MF, Argilagos RF, Koomen JM, McLaughlin ML, Hazlehurst LA.

Mol Cancer Ther. 2013 Nov;12(11):2446-58. doi: 10.1158/1535-7163.MCT-13-0310. Epub 2013 Sep 18.

12.

Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.

Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A, Han H, Francis R, Chakrasali R, Jakkaraj S, Kazi A, Sebti SM, Cubitt CL, Gebhard AW, Hazlehurst LA, Tash JS, Georg GI.

J Med Chem. 2013 May 23;56(10):3768-82. doi: 10.1021/jm301234k. Epub 2013 May 6.

13.

Emerging strategies for targeting cell adhesion in multiple myeloma.

Nair RR, Gebhard AW, Emmons MF, Hazlehurst LA.

Adv Pharmacol. 2012;65:143-89. doi: 10.1016/B978-0-12-397927-8.00006-3. Review.

PMID:
22959026
14.

High diagnostic value of synovial biopsy in periprosthetic joint infection of the hip.

Fink B, Gebhard A, Fuerst M, Berger I, Schäfer P.

Clin Orthop Relat Res. 2013 Mar;471(3):956-64. doi: 10.1007/s11999-012-2474-5. Epub 2012 Jul 18.

15.

Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.

Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE, Hazlehurst LA.

Mol Cancer Ther. 2011 Dec;10(12):2257-66. doi: 10.1158/1535-7163.MCT-11-0149. Epub 2011 Oct 6.

16.

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.

Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M.

Eur Respir J. 2011 Sep;38(3):516-28. doi: 10.1183/09031936.00073611. Epub 2011 Aug 4.

17.

Household expenditure and tuberculosis prevalence in VietNam: prediction by a set of household indicators.

Hoa NB, Tiemersma EW, Sy DN, Nhung NV, Gebhard A, Borgdorff MW, Cobelens FG.

Int J Tuberc Lung Dis. 2011 Jan;15(1):32-7.

PMID:
21276293
18.

Genetic association of DLG5 R30Q with familial and sporadic inflammatory bowel disease in men.

Lin Z, Poritz L, Franke A, Li TY, Ruether A, Byrnes KA, Wang Y, Gebhard AW, MacNeill C, Thomas NJ, Wu R, Schreiber S, Koltun WA.

Dis Markers. 2009;27(5):193-201. doi: 10.3233/DMA-2009-0662.

19.

Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts.

Kik SV, Franken WP, Mensen M, Cobelens FG, Kamphorst M, Arend SM, Erkens C, Gebhard A, Borgdorff MW, Verver S.

Eur Respir J. 2010 Jun;35(6):1346-53. doi: 10.1183/09031936.00098509. Epub 2009 Oct 19.

20.

Liquid culture for Mycobacterium tuberculosis: proceed, but with caution.

Anthony RM, Cobelens FG, Gebhard A, Klatser PR, Lumb R, Rüsch-Gerdes S, van Soolingen D.

Int J Tuberc Lung Dis. 2009 Sep;13(9):1051-3.

PMID:
19723391
21.

Genetic association of nonsynonymous variants of the IL23R with familial and sporadic inflammatory bowel disease in women.

Lin Z, Poritz L, Franke A, Li TY, Ruether A, Byrnes KA, Wang Y, Gebhard AW, MacNeill C, Thomas NJ, Schreiber S, Koltun WA.

Dig Dis Sci. 2010 Mar;55(3):739-46. doi: 10.1007/s10620-009-0782-8. Epub 2009 Mar 18.

PMID:
19294505
22.

EuroSCORE as a predictor for complications and outcome.

Gürler S, Gebhard A, Godehardt E, Boeken U, Feindt P, Gams E.

Thorac Cardiovasc Surg. 2003 Apr;51(2):73-7.

PMID:
12730814
23.

[Image analysis system for detection facial paralysis].

Suchy BH, Wolf SR, Gebhard A, Paulus D.

HNO. 2001 Oct;49(10):814-7. German.

PMID:
11699141
26.

Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation.

Klupp J, Bechstein WO, Pratschke J, Tullius SG, Gebhard A, Lobeck H, Langrehr JM, Neuhaus R, Neuhaus P.

Transplant Proc. 1998 Jun;30(4):1443-4. No abstract available.

PMID:
9636585
27.

Interrater reliability of the Peabody Developmental Motor Scales: fine motor scale.

Gebhard AR, Ottenbacher KJ, Lane SJ.

Am J Occup Ther. 1994 Nov-Dec;48(11):976-81.

PMID:
7530905
29.
30.

[On evaluating the umbilical position in newborn as a criterion of fetal maturity].

ERBSLOH J, BODMANN M, GEBHARD A.

Zentralbl Gynakol. 1954;76(24):929-34. German. No abstract available.

PMID:
13196599

Supplemental Content

Loading ...
Support Center